Cardiac Pathways searches for new financial strategy as it breaches bank loan conditions
This article was originally published in Clinica
Executive Summary
Cardiac Pathways, a pioneer in minimally-invasive integrated mapping and ablation systems for cardiac tachyarrhythmias, has breached the conditions of its bank loans and has hired Morgan Stanley as financial adviser to pursue strategic alternatives for its future. These include finding new capital for the Sunnyvale, California company, or selling it.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.